The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma

    Research output: Contribution to journalArticlepeer-review

    Abstract

    T cells genetically engineered to express tumour-targeting receptors are attractive anti-cancer therapeutic agents. Human T cells engrafted with a chimeric receptor specific for the B-cell lymphoma antigen CD19 fused to the CD3ζ receptor (aCD19z) are functional in vitro. Current successful clinical protocols targeting melanoma use pre-conditioning chemotherapy in combination with T cells. This study demonstrated that interleukin-2 expanded aCD19z T cells combined with cyclophosphamide effectively treated five-day established Raji B-cell lymphoma in an immunocompromised model system with 50% of mice surviving >100 days. This observation strongly supports the combination of antibody targeted T cells with chemotherapy as a novel approach for the therapy of CD19+ B-cell malignancies. © 2008 The Authors.
    Original languageEnglish
    Pages (from-to)65-68
    Number of pages3
    JournalBritish Journal of Haematology
    Volume142
    Issue number1
    DOIs
    Publication statusPublished - Jul 2008

    Keywords

    • Adoptive transfer
    • Chimeric receptor
    • Cyclophosphamide
    • Immunotherapy
    • Lymphoma

    Fingerprint

    Dive into the research topics of 'The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma'. Together they form a unique fingerprint.

    Cite this